Intuitive Surgical (ISRG) trades at $442.17 on November 3, 2026, about 2% below its post-earnings closing high, and the balance of evidence leans positive with high conviction. The stock sits above its 200-day average and the weekly uptrend, and it has outpaced both the S&P 500 and the healthcare ETF XLV over 50 days. A daily close above $448.17 on above-average volume would be the first sign that buyers are pushing through resistance.
Why it matters
The event was the third-quarter report in late October. Market Beat described revenue up 21.5% to just over $3 billion, more than 400 basis points above consensus, driven by procedures up 15% and device placements up 28%. Reported profit took a hit from a one-time class-action settlement impairment and from a pricing change the article expects to trim per-procedure figures. That is a strong top line with a margin question attached.
The market had already paid for much of it. The stock closed at $452.29 on October 23, 2026, its recent peak, and it is up 12.8% over one month. Since then it has eased to $442.17. Insider selling in the same window does not change that picture. Investing.com reported that the VP corporate controller sold $1.83 million of shares at $444.44 to $458.02 under a pre-arranged Rule 10b5-1 plan. The SEC filing on November 2 naming Aaron Martin of Humana to the board from January 1, 2027, is governance news, not a catalyst.
Over five days the stock is down 0.8%, while the S&P 500 (SPY) fell 2.1% and XLV rose 2.8%. So ISRG held up better than the market but trailed its sector by 3.7 points. Nothing in the filings or coverage explains that gap, and it looks like consolidation after a sharp run. The longer picture is weaker: the stock is down 21.9% this year, while SPY is up 10.5% and XLV is up 19.0%. The one-month rebound is repair, not a new leadership run.
The debate has two sides. The bulls point to growth: Zacks projects EPS growth of 25.9% this year against 10.9% for the industry and ranks the stock #2 (Buy). The Motley Fool noted that Cathie Wood's ARK added to its position on October 21. The cautious side rests on the margin hit and the pricing change, which are the reason a 21.5% revenue beat did not carry the stock higher on its own. On valuation, 30 analysts rate it a buy with a mean price target of $482.63, so the price is 8.4% below it. The targets run from $324 to $685, and that spread shows how little agreement there is on what the margins are worth.
What the evidence says
The long-term trend is up: price is above its 40-week average and its 200-day average of $432.07, and the thesis is intact but not repaired. The stock is 25.4% below its 52-week high of $592.85 and 33.2% above its low of $332.02. That places it in a recovery inside a damaged year, not a fresh advance. Against the S&P 500 it is still 1.7% behind over 200 days.
For the next 2 to 6 weeks the balance of evidence leans positive, and conviction is high at 3 of 4 points. The daily trend runs with the weekly uptrend. The stock leads the S&P 500 over 50 days by 11.3 points and leads XLV by 2.6 points. The RSI of 61.7 shows momentum without stretch, and the 50-day average at $404.08 sits well below price.
The strongest case against is participation. Volume is 58.5% below its 20-day average, so today's gain of 1.21% has little behind it. The stock also lags its sector over five days and sits just under a stack of resistance at $448.17 and $450. That is why conviction is 3 of 4 and not 4 of 4. It does not tip the balance because the price remains above the 200-day average, and the relative-strength evidence over 50 days is still on the stock's side.
Levels that matter
The structure holds above $432.07, the 200-day average, and a close below it would be the first crack. Under it sit $425 and then $417.12, a swing zone, and the trend ends below $417.12. The 50-day average at $404.08 and $400 lie further down but only matter once that line breaks.
The breakout level is a daily close above $448.17 on volume above the 20-day average, with $450 just above it. From there the first target is $458.44, then $538.26. The breakout would be wrong below $428.63, which is the 200-day average minus a quarter of the 14-day ATR of $13.75. Against that stop, the first target gives only 0.5 to 1 and the second gives 4.6 to 1. The math clears 3 to 1 only if the move reaches the far target, and $475 is a round-number obstacle along the way.
What would change the picture
The rule is a weekly close below $417.12, the swing zone where the trend ends. The non-price fact that would do it is evidence in company reporting that procedure growth has slipped well below the 15% of the third quarter, or that the pricing change is cutting per-procedure revenue by more than expected. Either would turn the margin question from a footnote into the central argument.
What to watch
- Earnings, January 21, 2027: procedure growth against the 15% reported in the third quarter is the number that matters.
- Sector: XLV is up 10.9% over one month and 19.0% this year, so ISRG's gap to the sector is the first thing to check before its own news. The GlobeNewswire market forecast on anti-obesity devices is a small reminder that GLP-1 drugs are part of the surgical backdrop.
- Valuation: the price sits 8.4% below the $482.63 mean target, inside a $324 to $685 range that shows how wide the disagreement is.